Health News

TALLAHASSEE, Fla.--(BUSINESS WIRE)--AHF: Florida Lawmakers Reach Deal to Reverse HIV Drug Cuts...

HALIFAX, NS--(BUSINESS WIRE)--Striking long term care workers from across Nova Scotia will be collapsing picket lines and converging outside of Premier Tim Houston’s state of the province address today. All Canadian Union of Public Employees (CUPE) members in Nova Scotia, community and political allies, as well as labour leaders will be speaking to the ‘state of long term care’ at a rally this afternoon. "It’s time our elected representatives listened to their constituents. We’re not just worke...

BORDEAUX, France--(BUSINESS WIRE)--TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. Th...

PARIS--(BUSINESS WIRE)--The 2026 China-Europe Seminar on Human Rights was held in Paris, France, on May 21. The event was jointly hosted by the China Society for Human Rights Studies and the Academy of Overseas Sciences, France. More than 150 representatives from over 20 countries and international organizations attended and held in-depth discussions on the theme “The Future of Human Rights under an Evolving International Order.” Shen Gang, Minister Counselor at the Chinese Embassy in France, s...

DENVER--(BUSINESS WIRE)--Virta Health Corp. and Virta Medical PC (hereinafter, collectively “Virta Health”) is providing this substitute notice as a result of a security incident to provide individuals with information and to share resources available for those who wish to further safeguard their personal information. The privacy and protection of information is a top priority for Virta Health. On March 24, 2026, Virta Health identified unauthorized activity limited to a data repository that is...

CHICAGO--(BUSINESS WIRE)--Access to evidence-based preventive services is central to delivering whole-person care and supporting long-term patient wellbeing. Representing more than 207,000 osteopathic physicians (DOs) and medical students in the U.S., we are deeply concerned by the abrupt dismissal of the United States Preventive Services Task Force (USPSTF) Vice Chairs and political interference in the USPSTF process. The USPSTF plays a critical role in healthcare coverage and access to servic...

SAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, today announced that new real-world evidence evaluating whole-genome sequencing-based homologous recombination deficiency phenotyping has been accepted for online publication at the 2026 American Society of Clinical Oncology Annual Meeting. The abstract, titled “Whole-genome HRD phenotyping as a predictor of PARP...

HYDERABAD, India & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced plans to open a new manufacturing facility in Hyderabad, India in 2027, create more than 300 direct jobs, and spend approximately $200 million in both ca...

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it has commenced an offer to exchange (the “Exchange Offers”) any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). Eligible Holders of 2029 Notes that participate in the New Money Notes Issuance (as defined below) will be able to exchange such 2029 No...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex® (bulevirtide-gmod) 8.5 mg for the treatment of adults living with chronic hepatitis delta virus (HDV) infection, making it the first and only approved treatment for HDV in the United States. The FDA granted accelerated approval to Hepcludex based on reductions in HDV RNA and normalization of alanine aminotrans...